Clinical Trials Browser

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Neoplasms, Neoplasms by Site, Recurrence, Urogenital Neoplasms, Urologic Diseases

Clinical Trials

A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy

An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants With aRCC (AVION)

CISTO

REASSURE

RAVI Registry

PRIORITY

IP3-PROSPECT

A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces

An Observational Study of Radiotherapy After Injection of SpaceOAR Hydrogel

PC-CONCEPT

Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma

A Study to Learn About the Study Medicine (Avelumab) in Japanese Patients With Urothelial Carcinoma That Has Spread

Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Systemic First-line (1st Line) Anti-cancer Treatment Under Daily Routine in Germany: Retrospective Medical Chart Review (RENALISTIC Study).

A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.

Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)

Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)

Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC

A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine.

OPTIMISE

TRACE

Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease

PET Imaging in MCI Following ADT for PCa

Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART)

Neutrophil-to-Lymphocyte Ratio in Bladder Cancer: A Secondary Biomarker Analysis of SWOG 8710

Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)

Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments

Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib

Evaluating the Shared Decision Making Process Scale in Cancer Screening Decisions

Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan

Online Trial Examining Validity and Reliability of the Shared Decision Making Process Survey

A Retrospective Medical Record Review of First-Line Sunitinib Administration Schedules and Outcomes Among Patients With mRCC in Latin America (LA)

PHRC2003

PROSTAGRAM

ATILA

TROYA

Optimizing the Effectiveness of Routine Post-treatment Surveillance in Prostate Cancer Survivors

Perioperative Hypogonadism in Men Undergoing Radical Cystoprostatectomy for Bladder Cancer

Retrospective Study on Referral Patterns for High Risk Patients Post Nephrectomy

Prostate Cancer Screening in Men With Germline BRCA2 Mutations

PREDYC

CABOBS

Circulating Tumor Cells in High-Risk Prostate Cancer Treated With High-dose Radiotherapy and Hormone Therapy

North Carolina Prostate Cancer Comparative Effectiveness & Survivorship Study (NC ProCESS)

RENACALL

PREDICT

PRIME

Observational Study Evaluating The Efficacy And Effects On Quality Of Life Of Targeted Treatments Following TKIs In mRCC